New drug ripertamab tested for muscle weakness disease
NCT ID NCT07372807
First seen Jan 31, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This early-phase trial tests if ripertamab can improve symptoms of generalized myasthenia gravis, a disease causing muscle weakness. About 20 adults with confirmed disease will receive a single infusion of ripertamab or a placebo. Researchers will track symptom changes and side effects over 13 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.